SpliceBio

SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡

Grateful to have supported this year's #BBQ2026 as a Silver Sponsor: the flagship summer gathering for Catalonia's biotech, healthtech & life sciences community. Thanks to @CataloniaHealth for another great edition. See you next year!

Ens fa molta il·lusió haver donat suport al #BBQ2026 a patrocinadors Silver: la gran trobada d’estiu de la comunitat biotecnològica, healthtech i de ciències de la vida de Catalunya. Gràcies a @CataloniaHealth per una altra fantàstica edició. Ens veiem l'any vinent!

Today is Rare Chromosome and Gene Disorder Awareness Day - a time to recognize the individuals and families affected by rare genetic conditions, including inherited retinal diseases such as #Stargardt disease. We honor their resilience and the importance of continued innovation.

🎧 Listen here: globalgenes.org/raredaily/fitt…

Our CEO Miquel Vila-Perello joined RARECast by @GlobalGenes to talk about why many rare diseases have long been out of reach for gene therapy and how SpliceBio is working to change that.

This Monday, we're in Leicester for @UKEyeGenetics Group (UK-EGG) 2026! Our CMO will present on conducting clinical trials, navigating the regulatory process and the importance of communication - fundamental elements to our mission of advancing #geneticmedicines.

Last week, our team came together for a retreat filled with reflection, connection, and plenty of laughs! Experiences like these reinforce something we believe deeply: investing in our people is essential to building a strong culture and advancing our mission.

#Stargardt disease is caused by mutations in ABCA4 - a gene too large for traditional gene therapy. We're advancing protein splicing to enable large-gene delivery and address the root cause of a disease with no approved treatments.

Great time at #ARVO2026 & #ASGCT2026! We were proud to share progress on our clinical program SB-007 for #Stargardt disease and engage in conversations with the broader #genetherapy community. Thank you to everyone who connected. We’re energized by the momentum!

#Stargardt disease has no approved treatments. This #HealthyVisionMonth, we’re raising awareness of inherited retinal diseases. At SpliceBio, we’re working to advance genetic medicines using protein splicing to address diseases caused by mutations in large genes.

We’re heading to #ASGCT2026 next week! Looking forward to connecting with the community, sharing insights, and contributing to the conversation around #genetherapy at the @ASGCTherapy Annual Meeting. See you there!

Great science starts with great people. Today, we celebrate the SpliceBio team whose passion and collaboration power our work in genetic medicines. Thank you for all you do. Happy #InternationalWorkersDay!

Happy #SantJordi and #WorldBookDay 🌹📖 Today, we’re celebrating a Catalan tradition of books, roses and storytelling with our team in Barcelona. Here’s to a day of love and culture, with roses for all!

Feliç #SantJordi i #WorldBookDay 🌹📖Avui celebrem una tradició catalana de llibres, roses i històries amb el nostre equip a Barcelona. Un dia per celebrar l’amor i la cultura, amb roses per a tothom!

Details: fightingblindness.org/events/innovat…

Our CMO Aniz Girach will present at the Annual Retinal Therapeutics Innovation Summit in Denver, co-hosted by @FightBlindness and @CaseyEye. He’ll share the progress of our clinical program SB-007, a third-generation intein-based dual AAV in development for Stargardt disease.

Watch here: checkrare.com/investigationa…

Our co-founder and CEO sat down with @CheckRare to discuss SB-007, our investigational dual-AAV gene therapy for #Stargardt disease, and how it is designed to enable delivery of the full-length ABCA4 protein.

Our work in genetic medicines is guided by shared values and scientific excellence. We’re grateful to the women at SpliceBio and to those everywhere whose work helps translate discovery into transformative therapies for patients.

We’re ready for an active week ahead engaging with the #biotech community! Logistics below. We look forward to sharing our progress and connecting with partners.